Patient characteristics and intervention in studies included in the review on cough attributed to treatment
| Study identification | Intervention | Number of patients | Age* | Number M/F | Cough present | OR | P value |
| Huland67 | Inhaled interleukin 2 | 15 | Early 40s to early 70s | 10 M 5 F | 13 of 15 | – | – |
| Wong68 | 2'-Deoxy-5-fluorouridine infusion | 3 | Late 40s, early 60s, mid-70s | 2 M 1 F | 2 | – | – |
| Merimsky69 | Inhaled interleukin 2 | 40 | 66.5 (range mid-40s to late 80s) | 30 M 10 F | 8 | – | – |
| Bukowski28 | Sorafenib versus placebo | 451 versus 452 | 59.1 (range late teens to mid-80s) versus 58.4 (range late 20s to mid-80s) | 315 M 136 F versus 340 M 112 F | SE 3.36 versus 3.11 | <0.0001 Favours sorafenib | |
| Esteban-Gonzalez29 | Inhaled interleukin 2 | 51 | 62 (range early 30s to early 80s) | 41 M 10 F | 399 of 1000 treatment cycles | – | – |
| Hudes65 | Temsirolimus versus IFN-α versus temsirolimus and IFN-α | 208 versus 200 versus 210 | 58 (range early 30s to early 80s) versus 60 (range early 20s to mid-80s) versus 59 (range early 30s to early 80s) | 139 M 70 F versus 148 M 59 F versus 145 M 65 F | †26 of 208 versus 14 of 200 versus 23/208 | – | – |
| Motzer60 | Everolimus versus placebo | 277 versus 139 | 61 (range late 20s to mid-80s) versus 60 (range late 20s to late 70s) | 216 M 61 F versus 106 M 33 F | 30 of 277 16 of 137 | 0.918522 | 0.398 |
| Muriel70 | CK (IFN-α) ± chemotherapy versus tyrosine kinase inhibitors (TKIs) (sunitinib and sorafenib) alone versus CK and TKI | 46 versus 28 versus 20 | 60 (range early 30s to late 70s) versus 60 (range early 40s to late 70s) versus 62 (range early 40s to mid-70s) | 39 M 7 F 21 M 7 F 16 M 4 F | CK 19/66 versus TKI 0/48 | – | – |
| Cauley26 | Everolimus | 86 | Not stated | 60 M 26 F | 14/24 who developed EAP | – | – |
| Ryan71 | Everolimus | 19 | 65 (range early 50s to late 70s) | 16 M 3 F | Seven of 19 | – | – |
| Saito72 | Everolimus | 1 | Mid-70s | 1 F | 1 | – | – |
| Atkinson73 | Temsirolimus versus everolimus versus both | 310 | 61 | 220 M 90 F | 26 of 310 | – | – |
| Kust74 | Sunitinib | 1 | Late 50s | 1 M | 1 | – | – |
| Levakov27 | Temsirolimus versus IFN-α | 30 versus 30 | Median age not stated (range late teens to mid-60s) | Not stated | 6/30 versus 3/30 | 2.25 | 0.143 |
| Powles61 | Apitolisib versus everolimus | 42 versus 43 | 61 (range mid-40s to mid-70s) versus 62 (range late 30s to early 90s) | 33 M 9 F versus 31 M 12 F | 4/42 versus 11/43 | 0.306220 | 0.03 |
| Escudier62 | Nivolumab initial treatment versus treatment despite disease progression | 153 versus 163 | 62 (range late 20s to mid-80s) versus 63 (range early 20s to mid-80s) | 116 M 37 F versus 128 M 35 F | 10/153 versus 11/163 | 0.966306 | 0.469 |
| Gutierrez75 | Nivolumab | 8 | 71 (range late 60s to mid-70s) | 6 M 2 F | 4 of 8 | – | – |
| Mendiola56 | Nivolumab | 1 | Late 50s | 1 M | 1 | – | – |
| Restuccia76 | Tivozanib | 17 | 70 (range late 40s to early 80s) | 13 M 4 F | 1 | – | – |
| Harada77 | Pazopanib | 1 | Mid-70s | 1 M | 1 | – | – |
| Watanabe78 | Nivolumab and ipilimumab | 1 | Late 70s | 1 F | 1 | – | – |
| Atkins79 | Axitinib and pembrolizumab | 52 | 63 | 41 M 11 F | 25 but 8 to treatment | – | – |
*To prevent patient identification, specific ages have been replaced by ‘early’/‘mid’/‘late’ ‘20s’, ‘30s’. Absolute values of median age are included where available.
†The patients analysed did not include those who underwent randomisation but did not receive treatment.29
EAP, everolimus-associated pneumonitis; F, female; IFN-α, interferon α; M, male.